Mostrar el registro sencillo del ítem
| dc.contributor.author | Tristan-Noguero, Alba | |
| dc.contributor.author | Fernández-Carasa, Irene | |
| dc.contributor.author | Calatayud, Carles | |
| dc.contributor.author | Bermejo-Casadesus, Cristina | |
| dc.contributor.author | Pons-Espinal, Meritxell | |
| dc.contributor.author | Baldeschi, Arianna-Colini | |
| dc.contributor.author | Campa, Leticia | |
| dc.contributor.author | Artigas, Francesc | |
| dc.contributor.author | Bortolozzi, Analia | |
| dc.contributor.author | Domingo-Jiménez, Rosario | |
| dc.contributor.author | Ibáñez, Salvador | |
| dc.contributor.author | Pineda, Mercè | |
| dc.contributor.author | Artuch, Rafael | |
| dc.contributor.author | Raya, Ángel | |
| dc.contributor.author | García-Cazorla, Ángels | |
| dc.contributor.author | Consiglio, Antonella | |
| dc.date.accessioned | 2025-11-20T12:48:32Z | |
| dc.date.available | 2025-11-20T12:48:32Z | |
| dc.date.issued | 2023-03 | |
| dc.identifier.citation | Tristán-Noguero A, Fernández-Carasa I, Calatayud C, Bermejo-Casadesús C, Pons-Espinal M, Colini Baldeschi A, et al. iPSC -based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation. EMBO Mol Med. 8 de marzo de 2023;15(3):e15847. | |
| dc.identifier.issn | 1757-4676 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21745 | |
| dc.description.abstract | Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management. | |
| dc.language.iso | eng | |
| dc.publisher | SPRINGERNATURE | |
| dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.subject.mesh | Levodopa/therapeutic use/metabolism | |
| dc.subject.mesh | Dopaminergic Neurons/metabolism | |
| dc.subject.mesh | Dystonic Disorders/congenital | |
| dc.subject.mesh | Phenotype | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Induced Pluripotent Stem Cells/metabolism | |
| dc.title | iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 36740977 | |
| dc.relation.publisherversion | https://www.embopress.org/doi/10.15252/emmm.202215847 | |
| dc.identifier.doi | 10.15252/emmm.202215847 | |
| dc.journal.title | Embo Molecular Medicine | |
| dc.identifier.essn | 1757-4684 |